Vivace Therapeutics
A venture-backed, oncology-focused portfolio-based drug discovery and development company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | $35.0m | Series D | |
| Total Funding | 000k | ||
Related Content
Vivace Therapeutics is a small molecule drug discovery and development company with a focus on oncology. The company is centered on creating new treatments for cancer patients by targeting specific biological pathways. Its main focus is on the Hippo-YAP pathway, which is a key regulator of cell growth and is often dysregulated in cancer.
Vivace Therapeutics' business model is based on a portfolio-based approach to drug discovery and development. This means that the company is developing multiple drug candidates at the same time, which helps to diversify risk and increase the chances of success. The company's primary customers are patients with advanced cancers, such as mesothelioma, who have limited treatment options. Vivace Therapeutics operates in the highly competitive oncology market, which is characterized by rapid innovation and a constant need for new and effective treatments.
Keywords: small molecule, drug discovery, oncology, cancer therapies, Hippo-YAP pathway, clinical development, mesothelioma, biopharmaceutical, therapeutics, cancer research